Company news: Alembic Pharmaceuticals

| Updated on December 02, 2019 Published on December 02, 2019

Alembic Pharmaceuticals on Monday announced that its joint venture Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application Diclofenac Sodium Topical Solution USP, 2% w/w. The drug is indicated for the treatment of the pain of osteoarthritis of the knees. Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of $974 million for 12 months ending December 2018, according to IQVIA. Shares of Alembic Pharma closed 0.48 per cent higher at ₹554.90 on the BSE.

Published on December 02, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.